October 24, 2018 / 5:06 AM / 24 days ago

BRIEF-Polyphor: Protocol Agreement With FDA For Second Pivotal Phase III Study Of Murepavadin

Oct 24 (Reuters) - Polyphor AG:

* EQS-ADHOC: POLYPHOR ANNOUNCES PROTOCOL AGREEMENT WITH THE FDA FOR THE SECOND PIVOTAL PHASE III STUDY OF MUREPAVADIN

* EXPECTS TO RECRUIT FIRST PATIENT BY Q119 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below